Lauren Sciences LLC, the private New York biotechnology company
developing breakthrough V-Smart™ Nanomedicines for brain diseases,
announced today the receipt of a grant from Voices Against Brain Cancer
(VABC). The grant will support the development of a V-Smart™ drug
delivery for glioblastoma multiforme (GBM), the most
aggressive malignant primary brain tumor in humans.
The Lauren Sciences’ research team and laboratories are located at
Ben-Gurion University of the Negev, where the V-Smart™ technology was
invented before it was licensed to Lauren Sciences.
“V-Smart™ for GBM, formulated with a potent anti-tumor agent, has
promise as an effective new treatment for GBM patients,” said Irwin
Hollander, Ph.D., vice president for research and development at Lauren
Sciences. “Our goal for this new V-Smart™ drug is to stop progression
of, or eradicate, GBM, unlike standard treatments that in the vast
majority of patients merely delay disease progression.“We anticipate future efficacy studies of V-Smart™ in GBM
pre-clinical models and, thereafter, clinical studies in patients. Our
goal is clinical validation and approval of this V-Smart™ for GBM.”
V-Smart™ for GBM will target and deliver a known chemotherapeutic
that has proven potential to treat the brain tumor, but does not cross
the blood-brain barrier (BBB) on its own. V-Smart™ Nanomedicines are
designed to target and deliver therapeutics across the BBB and into
selective brain cells both non-invasively and effectively.
No comments:
Post a Comment